Vladimir Bogin

Dr. Vladimir Bogin

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2008 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
TIThomas Ichim
Thomas Ichim
ZZZhaohui Zhong
Zhaohui Zhong
SKShalesh Kaushal
Shalesh Kaushal
XZXiufen Zheng
Xiufen Zheng
XRXiubao Ren
Xiubao Ren
RTRichard H Tullis
Richard H Tullis
Advances in cancer therapy have been substantial in terms of molecular understanding of disease mechanisms, however these advances have not translated into increased survival in the majority of cancer types. One unsolved problem in current cancer therapeutics is the substantial immune suppression seen in patients. Conventionally, investigations in this area have focused on antigen-nonspecific immune suppressive molecules such as cytokines and T cell apoptosis inducing molecules such as Fas ligand. More recently, studies have demonstrated nanovesicle particles termed exosomes are involved not only in stimulation but also inhibition of immunity in physiological conditions. Interestingly, exosomes secreted by cancer cells have been demonstrated to express tumor antigens, as well as immune suppressive molecules such as PD-1L and FasL. Concentrations of exosomes from plasma of cancer patients have been associated with spontaneous T cell apoptosis, which is associated in some situations with shortened survival. In this paper we place the "exosome-immune suppression" concept in perspective of other tumor immune evasion mechanisms. We conclude by discussing a novel therapeutic approach to cancer immune suppression by extracorporeal removal of exosomes using hollow fiber filtration technology

1 January 2010 in International Archives of Medicine
Verified
Journal Article
Open access
PDF file
TIThomas Ichim
Thomas Ichim
FSFabio Solano
Fabio Solano
FLFabian Lara
Fabian Lara
EPEugenia Paris
Eugenia Paris
FUFederico Ugalde
Federico Ugalde
NRNeil H Riordan
Neil H Riordan
Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recovery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to "D". This case supports further investigation into allogeneic-based stem cell therapies for SCI.

16 February 2010 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
FLFeng Lin
Feng Lin
SJSteven F Josephs
Steven F Josephs
DADoru T Alexandrescu
Doru T Alexandrescu
FRFamela Ramos
Famela Ramos
VBVladimir Bogin
Vladimir Bogin
DKDavid R Koos
David R Koos
The medical use of low level laser (LLL) irradiation has been occurring for decades, primarily in the area of tissue healing and inflammatory conditions. Despite little mechanistic knowledge, the concept of a non-invasive, non-thermal intervention that has the potential to modulate regenerative processes is worthy of attention when searching for novel methods of augmenting stem cell-based therapies. Here we discuss the use of LLL irradiation as a "photoceutical" for enhancing production of stem cell growth/chemoattractant factors, stimulation of angiogenesis, and directly augmenting proliferation of stem cells. The combination of LLL together with allogeneic and autologous stem cells, as well as post-mobilization directing of stem cells will be discussed.

1 June 2020 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
VBVladimir Bogin
Vladimir Bogin
A master protocol is a unifying study construct that includes multiple subgroups and substudies, with patients having same or different diseases and that employ one or multiple drugs to treat it. Initially designed for oncology, master protocol trials are intended to simultaneously evaluate more than one investigational drug and/or more than one cancer type within the same overall trial structure. The ability to use a single infrastructure, trial design, and protocol to simultaneously evaluate multiple drugs and/or disease populations in multiple substudies, speeds up drug development and makes it more efficient. Thus, it is important for the clinical trial professionals to understand both the basic principles of master protocol trials and the way innovative trial designs are starting to change the landscape of clinical research.

3 July 2020 in International Journal of Dermatology
Verified
Journal Article
Open access
PDF file
NPNikolai N. Potekaev
Nikolai N. Potekaev
OZOlga V. Zhukova
Olga V. Zhukova
DPDenis N. Protsenko
Denis N. Protsenko
ODOlga M. Demina
Olga M. Demina
EKElena A. Khlystova
Elena A. Khlystova
VBVladimir Bogin
Vladimir Bogin
Click on the article title to read more.

2 February 2022 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
VBVladimir Bogin
Vladimir Bogin
It has been over 40 years since Lasagna's Law was first introduced and its main postulates are still permeating the clinical trial arena.